Exploring the Th2 Response in Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease Pathway in Hypertension Development

• Published in: Life (Basel, Switzerland) Vol. 14; no. 9
• Main Authors: Méndez-García, Lucía Angélica, Escobedo, Galileo, Baltazar-Pérez, Itzel, Ocampo-Aguilera, Nydia Angélica, Arreola-Miranda, José Alfonso, Cid-Soto, Miguel Angel, Alfaro-Cruz, Ana, González-Chávez, Antonio, Ocaña-Guzmán, Aquiles Ranferi, Solleiro-Villavicencio, Helena
• Format: Journal Article
• Language: English
• Published: MDPI AG 01.09.2024
• Subjects: Angiotensin; Cytokines; Hypertension; Inflammation; Liver diseases; Obesity; Renin-angiotensin system; Type 2 diabetes; Mexico
• ISSN: 2075-1729; 2075-1729
• DOI: 10.3390/life14091080

Non-alcoholic fatty liver disease (NAFLD), now referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), is alarmingly increasing alongside the cases of obesity worldwide. MASLD is an underestimated metabolic abnormality closely linked with a higher risk of developing systemic arterial hypertension (SAH). However, the underlying mechanism of association between MASLD and SAH remains unknown. Inflammation may link these two entities by regulating the renin-angiotensin system (RAS). For this reason, in this study, we evaluated the hepatic expression of a cytokine profile and critical molecules in the RAS pathway in patients with morbid obesity and MASLD, both with SAH. We found a statistically significant correlation between ACE levels and the cytokines IL-4, IL-10, and IL-13 of Th2 response. Furthermore, according to a multiple linear regression analysis, the cytokines IL-4 and IL-13 were the best predictors of ACE levels. Moreover, we observed increased hepatic IL-13 expression in patients with morbid obesity, MASLD, and SAH compared to those without SAH. These results allow us to propose, for the first time, that the Th2 response, through regulating the RAS, could play a critical role in developing SAH in individuals with MASLD and obesity.